

# Isolation and *in Vitro* Characterization of Specific Bacteriophages against Methicillin-Resistant *Staphylococcus aureus*

## ARTICLE INFO

### Article Type Original Article

### Authors

Mohammad Reza Esmailzadeh, MSc<sup>1</sup>  
Samira Sabzi, PhD<sup>2\*</sup>  
Aida Hajhossein Tabrizi, MSc<sup>3</sup>

### How to cite this article

Esmailzadeh MR, Sabzi S, Hajhossein Tabrizi A. Isolation and *in Vitro* Characterization of Specific Bacteriophages against Methicillin-Resistant *Staphylococcus aureus*. Infection Epidemiology and Microbiology. 2022;8(2): 121-128

<sup>1</sup> Department of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

<sup>2</sup> Department of Molecular Biology, Pasteur Institute, Tehran, Iran

<sup>3</sup> Department of Biology, School of Basic Sciences, Islamic Azad University, Qods city Branch, Tehran, Iran

### \* Correspondence

Address: Samira Sabzi, Department of Molecular Biology, Pasteur Institute, Tehran, Iran  
Email: s\_sabzi@Pasteur.ac.ir

### Article History

Received: December 04, 2021  
Accepted: January 23, 2023  
Published: June 22, 2022

## ABSTRACT

**Backgrounds:** Bacteriophage therapy could be an alternative strategy for the treatment of antibiotic-resistant bacteria. This study aimed to evaluate the antibacterial activities of isolated bacteriophages against methicillin-resistant *Staphylococcus aureus* (MRSA) isolates.

**Materials & Methods:** A total of 16 clinical isolates of MRSA were collected from medical diagnostic laboratories in Tehran, Iran. A specific bacteriophage was isolated from hospital sewage using double-layer agar. Phage morphology was evaluated by transmission electron microscopy (TEM). Different bacteria were selected to determine the bacteriophage host range using spot test. Phage susceptibility to temperature and pH was evaluated by double-layer agar method. *In vitro* assay was carried out on human epithelial type 2 (HEp-2) cells to investigate the effect of bacteriophage on the adhesion of MRSA to human epithelial cells.

**Findings:** TEM suggested the *Myoviridae* family for the isolated phage. The effective titer of bacteriophages was  $1.8 \times 10^7$  PFU/mL. The isolated bacteriophage was stable at 4 °C and pH=8. The isolated bacteriophage was specific for all clinical isolates of MRSA and had no lytic activity against other pathogenic bacteria. In evaluating the binding and invasion of MRSA to the HEp-2 cell line, as expected, the lytic activity of specific bacteriophages was observed following inoculation.

**Conclusion:** The specificity and lytic activity of this phage on MRSA and MRSA-infected HEp-2 cell line emphasized that the isolated bacteriophage may serve as an effective prophylactic and alternative therapeutic agent in hospital settings.

**Keywords:** Methicillin-resistant *Staphylococcus aureus*, Bacteriophage, Phage therapy

## CITATION LINKS

[1] Davies J, Davies D. Origins and evolution of ... [2] David MZ, Daum RS. Community-associated methicillin-resistant *Staphylococcus aureus*: Epidemiology ... [3] Askari E, Soleymani F, Arianpoor A, Tabatabai SM, Amini A, Naderi Nasab M. Epidemiology ... [4] Li B, Webster TJ. Bacteria antibiotic ... [5] Moghadam MT, Khoshbayan A, Chegini Z, Farahani I, Shariati A. Bacteriophages, a new ... [6] Summers WC. Félix d'Hérelle and ... [7] Ho K. Bacteriophage therapy for bacterial ... [8] Merril CR, Biswas B, Carlton R, Jensen NC, Creed GJ, Zullo S, et al. Long ... [9] Drulis-Kawa Z, Majkowska-Skrobek G, Maciejewska B, Delattre AS, Lavigne R. Learning from bacteriophages-advantages and limitations of ... [10] Divya Ganeshan S, Hosseinidoust Z. Phage therapy with a ... [11] Lin DM, Koskella B, Lin HC. Phage therapy: An ... [12] Weber-Dąbrowska B, Mulczyk M, Górski A. Bacteriophage therapy ... [13] Romero-Calle D, Guimarães Benevides R, Góes-Neto A, Billington C. Bacteriophages as ... [14] Wong CL, Sieo CC, Tan WS, Abdullah N, Hair-Bejo M, Abu J, et al. Evaluation of ... [15] Wagenaar JA, Van Bergen MA, Mueller MA, Wassenaar TM, Carlton RM. Phage ... [16] Tahmasbi F, Sheikhi R, Ashraf A, Mojtahedi A. Biofilm formation and molecular characterization of ... [17] Wang Z, Zheng P, Ji W, Fu Q, Wang H, Yan Y, et al. SLPW: A ... [18] Nobrega FL, Costa AR, Kluskens LD, Azeredo J. Revisiting ... [19] Shende R, Hirpurkar S, Sannat C, Rawat N, Pandey V. Isolation and ... [20] Smith HW, Huggins MB, Shaw KM. The control of ... [21] Deghorain M, Van Melderen L. The staphylococci phages ... [22] Melo LD, Brandão A, Akturk E, Santos SB, Azeredo J. Characterization of ... [23] Kraushaar B, Thanh MD, Hammerl JA, Reetz J, Fetsch A, Hertwig S. Isolation and characterization of ... [24] Nasser A, Azizian R, Tabasi M, Khezerloo JK, Heravi FS, Kalani MT, et al. Specification of ... [25] Ptashne M. Lambda's ... [26] Łubowska K, Grygorcewicz B, Kosznik-Kwaśnicka K, Zauszkiewicz-Pawlak A, Węgrzyn A, Dołęgowska B, et al. Characterization ... [27] Paolozzi L, Ghelardini P. The bacteriophage ... [28] Jończyk E, Kłak M, Międzybrodzki R, Górski A. The influence of external ... [29] Nasu-Nishimura Y, Taniuchi Y, Nishimura T, Sakudo A, Nakajima K, Ano Y, et al. Cellular ... [30] Chandni P, Amrita S, Archana PV, Pradeesh B, Bipin N, Ajith M, et al. Characterization ...

## Introduction

*Staphylococcus aureus* is a Gram-positive bacterium that could cause minor to life-threatening infections. *S. aureus* infections were initially easily treated with penicillin, but over time and with the indiscriminate use of antibiotics, resistant strains were emerged [1]. Today, infections caused by methicillin-resistant *S. aureus* (MRSA) strains are spreading rapidly, and treatment of these infections is more difficult [2]. In a meta-analysis study in Iran, about 7500 *S. aureus* isolates were collected from patients in different places, of which about 54% of the isolates carried the *mec* gene, causing resistance to methicillin [3]. Resistant infections in various tissues and organs that could not be treated with antibiotics are considered important healthcare problems that could endanger human life [4]. In this situation, alternative treatment options and antibacterial agents must be developed. Additionally, because bacteria rapidly become resistant to new antibiotics, as well as due to the high costs of producing antibiotics, there must be a minimal motivating force to develop new antibiotics [5].

Bacteriophage (phage) is a virus that attacks bacterial cells and induces cell lysis. Phage therapy was initially presented by Felix d'Herelle (1999) over a century ago [6, 7]. The antibacterial effect of bacteriophages has been well known since their discovery [8]. Bacteriophages have surface receptors on bacterial cells for binding, including lipopolysaccharide (LPS), peptidoglycan, outer membrane proteins, oligosaccharides, capsules, and type IV fimbria [9]. Also, phage therapy could be considered as a treatment option without major side effects on microbiota and eukaryotic cells [10, 11]. Furthermore, due to detailed and extensive studies, the limitations of phage therapy have been removed, which has made them good options for use in treatment systems [12, 13].

**Objektivives:** The present study aimed to characterize and *in vitro* evaluate the isolated specific bacteriophage and its antibacterial activities against MRSA isolates.

## Materials and Methods

**Bacterial preparation and susceptibility testing:** In this study, 16 clinical isolates of MRSA from different sources were collected from medical diagnostic laboratories in Tehran, Iran. The standard strain of *S. aureus* (ATCC 33591) was selected as a positive control, and all isolates were confirmed by catalase, coagulase, oxidase, and DNase production as well as mannitol fermentation. E-test (Liofilchem s.r.l, Roseto Degli Abruzzi, Italy) was carried out to verify resistance to methicillin, suggested by the Clinical and Laboratory Standards Institute (CLSI) guidelines.

**Bacteriophage isolation and purification:** To isolate specific bacteriophages, a wastewater sample was collected from the hospital and sent to the laboratory immediately. Then the sample was placed in a refrigerator overnight to settle the sediments. The sample was centrifuged (Sigma, Germany) at 4°C and ×15,000 g and then passed through a 0.22-micrometer filter (Jet-Biofiltration, China). Then 15 mL of the centrifuged solution and bacterial suspension (containing 10<sup>6</sup> CFU/mL of MRSA) from a 12-hour culture were added to the brain-heart infusion (BHI) medium (Merck, Germany) with 0.7% agar and then to a plate containing BHI broth with 1.5% agar [14]. After 24 hours, plaques were observed and removed using a sterile pipette. These plaques were added to BHI broth for enrichment, and enriched phage was then used to assess plaque formation. For phage purification, all steps were repeated five times, and the phage solution was stored at 4°C until used for further studies [15].

**Morphological assessment of the phage:**

The isolated bacteriophage was examined for size and morphology using a transmission electron microscope (TEM; 150 kV Philips-CM 30, Germany). For this purpose, a drop of phage was poured on a carbon-coated copper gride and then painted with 2% uranyl acetate.

**Bacteriophage titration:** Bacteriophage titration was carried out in three steps. First, *S. aureus* was inoculated on LB agar and plated at 37°C for 24 hrs. Then a single colony of the bacterium was inoculated in 25 mL of tryptone broth at 37°C. Finally, 1 mL of SM buffer was pipetted in a tube, and a dilution of 10<sup>-10</sup> was prepared using serial dilution. Besides, 300 µL of bacterial culture was poured in 9 tubes, and 100 µL of each dilution was serially added to each tube. The tubes were then vortexed and placed at room temperature for 20 minutes.

The tubes were labeled, and 4 mL of molten agar (40-50 °C) was poured in tube No. 1 and vortexed. Then the suspension was transferred to LB agar plate using a sterile pipette. This procedure was carried out for each dilution, and the plates were incubated at 37°C. Finally, a plaque assay was carried out to determine plaque formation.

**Phage susceptibility to heat:** A certain concentration (aliquot) of phage suspension (1×10<sup>8</sup> CFU/mL) was incubated at 4, 25, 37, 50, 60, and 70°C and pH=7 for 60 min. Bacteriophage titration was carried out using the double-layer agar method. All experiments were performed in triplicate.

**Phage susceptibility to PH:** A certain concentration (aliquot) of phage suspension (1×10<sup>8</sup> CFU/ml) was incubated at 4°C in the pH range of 3 to 12 for 60 min. Bacteriophage titration was carried out using double-layer agar. All experiments were performed in triplicate.

**Determining the host range of bacteriophage:** Different bacterial standard strains

were obtained from the Pasteur Institute of Iran, and the spot test was performed to determine the host range of bacteriophage. For this purpose, *Salmonella enterica* serovar Typhimurium (ATCC14028), *Shigella dysenteriae* (ATCC13313), *Citrobacter freundii* (ATCC43864), Enteropathogenic *Escherichia coli* (ATCC35401), *Enterococcus faecalis* (ATCC29212), *Listeria monocytogenes* (ATCC19114), *Cronobacter sakazakii* (ATCC29544), *S. aureus* (ATCC 33591), and 16 clinical isolates of MRSA were used. Each bacterial species was inoculated in BHI broth for 24 hrs. Then 100 µL of bacterial culture was added to 4 mL of BHI agar, and double-layer agar was prepared after pouring into the plate with BHI agar. Then 10 µL of bacteriophage suspension was spotted, and the plates were incubated at 37°C for 24 hrs. In addition, sensitivity to bacteriophages was determined based on the formation of the inhibition zone. All experiments were carried out in triplicate.


**Bacterial adherence and the effect of a specific bacteriophage using HEp-2 cell line:** Bacterial adhesion assay was carried out *in vitro* on human epithelial type 2 (HEp-2) cells to assess the effect of bacteriophage on MRSA adherence to human epithelial cells. HEp-2 cells were obtained from the cell bank of the Pathobiology Department, School of Public Health of Tehran University of Medical Sciences (Tehran, Iran). In the next step, the cells were added to the culture flasks containing minimum essential medium (MEM; Sigma-Aldrich, USA), 10% fetal bovine serum (Sigma-Aldrich, USA), penicillin (100U/mL) (Sigma-Aldrich, USA), and streptomycin (100 µg/mL) (Sigma-Aldrich, USA); then they were protected at 37°C with %5 CO<sub>2</sub>. After the cell line accomplishment, the cells were trypsinized and counted. Then 2×10<sup>5</sup> cells were added into each vial of 12-cell plates and stored at 37°C with %5 CO<sub>2</sub>. Afterward the culture medium was removed from the



cells, and the vials were washed twice with phosphate-buffered saline (PBS) solution. The vial without the bacteria and phage was selected as a negative control. Moreover, 150  $\mu\text{L}$  of MRSA suspension ( $1-2 \times 10^8$  CFU/mL) was added to well A, and 150  $\mu\text{L}$  of MRSA suspension ( $1-2 \times 10^8$  CFU/mL) plus 150  $\mu\text{L}$  of the phage solution ( $10^6$  pfu/mL) was added to well B. The plate was stored at 37  $^\circ\text{C}$  for 4-3 hrs. After incubation, the cells were washed with PBS to remove unattached bacteria; after fixation with methyl alcohol, they were finally stained with crystal violet staining (Merck, Germany).

## Results

**Antibiotic susceptibility testing:** MRSA isolates were confirmed by cefoxitin E-test according to the CLSI guideline (Fig. 1). MIC of  $\geq 8$   $\mu\text{g}/\text{mL}$  was considered as MRSA.




**Fig. 1)** MIC test strip of cefoxitin (FOX strip, 0.002-32  $\mu\text{g}/\text{mL}$ ). MRSA isolates had MIC of  $>8$   $\mu\text{g}/\text{mL}$

### Determination of bacteriophage morphology:

Using microscopy, bacteriophages were observed with an icosahedral head of approximately 46 and 90 nm along with a very short tail. Transmission electron microscopy showed that isolated bacteriophages belonged to the *Myoviridae*

family (Fig. 2).



**Fig. 2)** Morphology of phage (*Myoviridae* family) using TEM

**Bacteriophage titration:** Based on the double-layer agar assay, the titer of bacteriophages was  $1.8 \times 10^7$  PFU/mL. To be able to report the number of plaques, 30-300 plaques should be formed on the media (Table 1). Bacterial dilution of  $10^4$  was used to report the number of phages according to the following formula:

Number of Viruses (phages) in 1mL suspension

$$= \frac{\text{number of plaques}}{\text{dilution factor} \times \text{phage solution volume}} = \frac{180}{0.0001 \times 0.1}$$

The number of phages in 1 mL of suspension =  $1.8 \times 10^7$  PFU/mL


**Table 1)** Number of bacteriophage plaques in each sample

	Number of plaques in different dilutions of bacteriophage suspensions		
Dilution of specific bacteriophage	$10^4$	$10^5$	$10^6$





to the effect of isolated bacteriophages on MRSA-infected HEP-2 cell line, it was found that bacteriophages showed a good ability to reduce and eliminate the studied bacteria (Fig. 5). The bactericidal effects of isolated bacteriophages against MRSA were evaluated as completely positive, and infected HEP-2 cell lines lost their original state (deformation), and intercellular connections were largely lost.



**Fig. 5)** Effect of isolated bacteriophages on bacterial adhesion to HEP-2 cells. **A:** MRSA adhesion to HEP-2 cells. **B:** HEP-2 cells after inoculation of MRSA and phage (no bacterial adhesion to cells in the exposure of phage).

**Table 4)** Effect of isolated bacteriophages on the studied bacteria

Bacteria	Lysis
<i>Salmonella enterica</i> serovar Typhimurium	-
<i>Staphylococcus aureus</i> (ATCC 33591)	+
<i>Shigella dysenteriae</i>	-
Enteropathogenic <i>E. coli</i> (EPEC)	-
<i>Citrobacter freundii</i>	-
<i>Enterococcus faecalis</i>	-
<i>Listeria monocytogenes</i>	+
MRSA isolates	+
<i>Cronobacter sakazakii</i>	-

## Discussion

*S. aureus* is typically the cause of many human and animal infections ranging from

modest to more important situations such as bacteremia, endocarditis, pneumonia, and bone and joint infections [16]. The emergence of resistant bacterial strains such as MRSA highlights the need for improving treatment methods in the future [17]. Bacteriophages are a type of viruses that use and attack bacteria as hosts. Thus, phage therapy could be a good candidate to combine with traditional therapies [18, 19]. Smith et al. (1987) showed that the use of a single intramuscular dose of anti-K phage was more effective in treating muscle infection in mice than treatment with multiple doses of tetracycline, chloramphenicol, trimethoprim, as well as sulfafurazole [20]. In this study, a specific phage was isolated and tested against MRSA strains. This bacteriophage morphologically belonged to the *Myoviridae* family. The high ability of the *Myoviridae* family to lyse bacteria makes them the best candidates for phage therapy purposes [21, 22]. In a similar study, an anti-MRSA specific phage was isolated from animals and observed using an electron microscope, and its lytic properties against MRSA were evaluated, but it belonged to the *Podoviridae* family [23]. In another investigation, two novel phages belonging to the *Siphoviridae* family were isolated from the farm and showed lytic properties against MRSA [24]. Like all viruses, bacteriophages are species-specific and usually infect a single species of bacteria [25]. In this study, phage specificity test was performed using spot test based on the formation of an inhibition zone. The pathogenic bacteria examined in this study for this purpose were as follows: *S. enterica* serovar Typhimurium, *S. dysenteriae*, *C. freundii*, Enteropathogenic *E. coli*, *E. faecalis*, *L. monocytogenes*, *C. sakazakii*, *S. aureus* ATCC 33591, as well as 16 clinical isolates of MRSA. It was shown that all MRSA isolates were susceptible to this bacteriophage, while other bacteria showed no sensitivity. These results are in line with the findings of a

study by Lubowska et al. (2019) [26], but they are inconsistent with the results of another study by Paolozzi and Ghelardini (2006) [27]. External factors such as pH and temperature are very crucial for bacteriophage function and survival. At temperatures below and pHs above the optimal values, less phage genetic material penetrates bacterial host cells [28]. Another purpose of this investigation was to assess the phage function at various temperatures and pH values. According to the results, the isolated phage showed the highest stability at refrigerator temperature. However, it could survive at 25 and 37°C, but its count decreased at a temperature of 50-70°C, and it was destroyed at 80-90 °C. Furthermore, the highest level of lytic activity of bacteriophages was at pH 6 to 8. Therefore, it has an optimal function at physiological pH. Bacteriophages could potentially be applied to decrease infection in various tissue microenvironments. Many different challenges, including cytotoxicity and administrative issues, remain confusing before bacteriophage therapy could be credited among new medications [29]. In this study, the efficacy of the isolated phage was investigated *in vitro* using HEp-2 cells line. Phage-treated cells showed similar results and cell morphology to untreated cells after 2 and 24 hrs of incubation. The isolated bacteriophage capacity to cover mammalian cells against MRSA infection was studied using HEp-2 cells. The results showed a decrement in MRSA-infected HEp-2 cells undergoing phage pre-treatment. Based on the results, the isolated phage could potentially diminish the bacterial burden compared to the phage-undressed HEp-2 cells. This study was assessed with regards to the treatment and control of infections. However, more investigation and *in vivo* studies are required to accurately identify bacteriophage benefits.

## Conclusion

This study showed that isolated bacteriophages could lyse MRSA strains *in vitro*. The emergence of antibiotic resistant *S. aureus* strains suggests that bacteriophages may serve as an alternative solution to this medical dilemma. However, these isolated phages need to be further characterized, and if found to be effective, they could be widely used commercially as an effective antibacterial agent.

## Acknowledgment

We sincerely thank the effort of Pedram Foroughi Shad, head of the Research Department of the Central Organization of Community-Wide Science Ambassadors, Department of Medical Biology Research, Tehran, Iran.

**Ethical Permissions:** This article does not contain any studies with human participants and animals.

**Conflicts of Interest:** The authors declare no conflict of interest.

**Authors' Contribution:** Conceptualization: SS; data curation: AHH; formal analysis: AHH; funding acquisition: SS; investigation: SS; methodology: MRE ; project administration: SS; writing of the original draft: MRE; writing-review and editing: MRE.

**Fundings:** his study was supported by Research Department of the Central Organization of Community-Wide Science Ambassadors, Department of Medical Biology Research, Tehran, Iran.

**Consent to participate:** This article does not contain any individual person's data in any form.

## References

1. Davies J, Davies D. Origins and evolution of antibiotic resistance. *Microbiol Mol Biol Rev.* 2010;74(3):417-33
2. David MZ, Daum RS. Community-associated methicillin-resistant *Staphylococcus aureus*: Epidemiology and clinical consequences of an emerging epidemic. *Clin Microbiol Rev.* 2010;23(3):616-87.
3. Askari E, Soleymani F, Arianpoor A, Tabatabai SM,

- Amini A, NaderiNasab M. Epidemiology of mecA-methicillin resistant *Staphylococcus aureus* (MRSA) in Iran: A systematic review and meta-analysis. *Iran J Basic Med Sci.* 2012;15(5):1010-9.
4. Li B, Webster TJ. Bacteria antibiotic resistance: New challenges and opportunities for implant-associated orthopedic infections. *J Orthop Res.* 2018;36(1):22-32.
  5. Moghadam MT, Khoshbayan A, Chegini Z, Farahani I, Shariati A. Bacteriophages, a new therapeutic solution for inhibiting multidrug-resistant bacteria causing wound infection: Lesson from animal models and clinical trials. *Drug Des Dev Ther.* 2020;14:1867-83.
  6. Summers WC. Félix d'Hérelle and the origins of molecular biology. New Haven: Yale University Press; 1999.
  7. Ho K. Bacteriophage therapy for bacterial infections: Rekindling a memory from the pre-antibiotics era. *Perspect Biol Med.* 2001;44(1):1-16.
  8. Merrill CR, Biswas B, Carlton R, Jensen NC, Creed GJ, Zullo S, et al. Long-circulating bacteriophage as antibacterial agents. *Proc Natl Acad Sci.* 1996;93(8):3188-92.
  9. Drulis-Kawa Z, Majkowska-Skrobek G, Maciejewska B, Delattre AS, Lavigne R. Learning from bacteriophages-advantages and limitations of phage and phage-encoded protein applications. *Curr Protein Pept Sci.* 2012;13(8):699-722.
  10. Divya Ganeshan S, Hosseinidoust Z. Phage therapy with a focus on the human microbiota. *J Antibiot.* 2019;8(3):131.
  11. Lin DM, Koskella B, Lin HC. Phage therapy: An alternative to antibiotics in the age of multi-drug resistance. *World J Gastrointest Pharmacol Ther.* 2017;8(3):162-73.
  12. Weber-Dąbrowska B, Mulczyk M, Górski A. Bacteriophage therapy of bacterial infections: An update of our institute's experience. *Arch Immunol Ther Exp.* 2000;48(6):547-51.
  13. Romero-Calle D, Guimarães Benevides R, Góes-Neto A, Billington C. Bacteriophages as alternatives to antibiotics in clinical care. *J Antibiot.* 2019;8(3):138.
  14. Wong CL, Sieo CC, Tan WS, Abdullah N, Hair-Bejo M, Abu J, et al. Evaluation of a lytic bacteriophage,  $\Phi$  st1, for biocontrol of *Salmonella enterica* serovar Typhimurium in chickens. *Int J Food Microbiol.* 2014;172:92-101.
  15. Wagenaar JA, Van Bergen MA, Mueller MA, Wassenaar TM, Carlton RM. Phage therapy reduces *Campylobacter jejuni* colonization in broilers. *Vet Microbiol.* 2005;109(3):275-83.
  16. Tahmasbi F, Sheikhi R, Ashraf A, Mojtahedi A. Biofilm formation and molecular characterization of methicillin-resistant *Staphylococcus aureus* strains isolated from the patients, personnel, air, and environment of ICUs. *Gene Rep.* 2020;20:100736.
  17. Wang Z, Zheng P, Ji W, Fu Q, Wang H, Yan Y, et al. SLPW: A virulent bacteriophage targeting methicillin-resistant *Staphylococcus aureus* in vitro and in vivo. *Front Microbiol.* 2016;7:934.
  18. Nobrega FL, Costa AR, Kluskens LD, Azeredo J. Revisiting phage therapy: New applications for old resources. *Trends Microbiol.* 2015;23(4):185-91.
  19. Shende R, Hirpurkar S, Sannat C, Rawat N, Pandey V. Isolation and characterization of bacteriophages with lytic activity against common bacterial pathogens. *Vet World.* 2017;10(8):973-8.
  20. Smith HW, Huggins MB, Shaw KM. The control of experimental *Escherichia coli* diarrhoea in calves by means of bacteriophages. *J Gen Microbiol.* 1987;133(5):1111-26.
  21. Deghorain M, Van Melder L. The staphylococci phages family: An overview. *Viruses.* 2012;4(12):3316-35.
  22. Melo LD, Brandão A, Akturk E, Santos SB, Azeredo J. Characterization of a new *Staphylococcus aureus* Kayvirus harboring a lysin active against biofilms. *Viruses.* 2018; 10(4):182-98.
  23. Kraushaar B, Thanh MD, Hammerl JA, Retz J, Fetsch A, Hertwig S. Isolation and characterization of phages with lytic activity against methicillin-resistant *Staphylococcus aureus* strains belonging to clonal complex 398. *Arch Virol.* 2013;158(11):2341-50.
  24. Nasser A, Azizian R, Tabasi M, Khezerloo JK, Heravi FS, Kalani MT, et al. Specification of bacteriophage isolated against clinical methicillin-resistant *Staphylococcus aureus*. *Osong Public Health Res Perspect.* 2019;10(1):20-4.
  25. Ptashne M. Lambda's switch: Lessons from a module swap. *Curr Biol.* 2006;16(12):459-62.
  26. Łubowska N, Grygorcewicz B, Kosznik-Kwaśnicka K, Zauszkiewicz-Pawłak A, Węgrzyn A, Dołęgowska B, et al. Characterization of the three new kayviruses and their lytic activity against multidrug-resistant *Staphylococcus aureus*. *Microorganisms.* 2019;7(10):471-88.
  27. Paolozzi L, Ghelardini P. The bacteriophage Mu. In: Calendar R, Abedon ST, editors. *The bacteriophages.* Oxford: Oxford University Press; 2006.
  28. Jończyk E, Kłak M, Międzybrodzki R, Górski A. The influence of external factors on bacteriophages-review. *Folia Microbiol.* 2011;56(3):191-200.
  29. Nasu-Nishimura Y, Taniuchi Y, Nishimura T, Sakudo A, Nakajima K, Ano Y, et al. Cellular prion protein prevents brain damage after encephalomyocarditis virus infection in mice. *Arch Virol.* 2008;153(6):1007-12.